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Abstract
Background: Molecular alterations critical to development of cancer include mutations, copy number alterations
(amplifications and deletions) as well as genomic rearrangements resulting in gene fusions. Massively parallel next
generation sequencing, which enables the discovery of such changes, uses considerable quantities of genomic DNA
(> 5 ug), a serious limitation in ever smaller clinical samples. However, a commonly available microarray platforms
such as array comparative genomic hybridization (array CGH) allows the characterization of gene copy number at a
single gene resolution using much smaller amounts of genomic DNA. In this study we evaluate the sensitivity of
ultra-dense array CGH platforms developed by Agilent, especially that of the 1 million probe array (1 M array), and
their application when whole genome amplification is required because of limited sample quantities.
Methods: We performed array CGH on whole genome amplified and not amplified genomic DNA from MCF-7
breast cancer cells, using 244 K and 1 M Agilent arrays. The ADM-2 algorithm was used to identify micro-copy
number alterations that measured less than 1 Mb in genomic length.
Results: DNA from MCF-7 breast cancer cells was analyzed for micro-copy number alterations, defined as
measuring less than 1 Mb in genomic length. The 4-fold extra resolution of the 1 M array platform relative to the
less dense 244 K array platform, led to the improved detection of copy number variations (CNVs) and micro-CNAs.
The identification of intra-genic breakpoints in areas of DNA copy number gain signaled the possible presence of
gene fusion events. However, the ultra-dense platforms, especially the densest 1 M array, detect artifacts inherent
to whole genome amplification and should be used only with non-amplified DNA samples.
Conclusions: This is a first report using 1 M array CGH for the discovery of cancer genes and biomarkers. We show
the remarkable capacity of this technology to discover CNVs, micro-copy number alterations and even gene
fusions. However, these platforms require excellent genomic DNA quality and do not tolerate relatively small
imperfections related to the whole genome amplification.
Background
Recent advances in genomics have dramatically
increased our capacity to analyze both normal and
cancer cells, revealing a multitude of changes in geno-
mic DNA, such as mutations and copy number altera-
tions (CNAs). One of the most exciting discoveries of
the last 5 years has been the discovery of the important
role of DNA copy number variations or polymorphisms
(CNVs) in determining predisposition to diseases such
as autism, HIV infection and glomerulonephritis [1-4].
Moreover, the characterization of molecular alterations
specific to cancer has enabled the discovery of novel
predictive and prognostic biomarkers, which are becom-
ing an integral part of the development of novel targeted
therapeutics in cancer. Molecular alterations critical to
cancer therapeutics include CNAs such as gene amplifi-
cations and deletions as well as genomic rearrangements
resulting in gene fusions. DNA amplifications have been
shown to contain important druggable oncogenes, such
as the genes encoding for the HER2 and EGF receptors
[5,6]. The discovery of chromosomal translocations in
solid tumors, such as the one involving the ALK gene
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adenocarcinoma, have also led to the development of
very promising novel therapies directed against these
changes [7,8]. Although massively parallel next genera-
tion sequencing enables the discovery of such changes
[9], this technology remains expensive, requires exten-
sive bioinformatics support, uses considerable quantities
of genomic DNA (> 5 ug), and is not easily accessible.
On the other hand, a commonly available microarray
platform such as array comparative genomic hybridiza-
tion (array CGH) allows the characterization of gene
copy number at a single gene resolution using as little
as 0.5 μg of genomic DNA [10]. Such sensitivity
becomes important when one considers that genomics
technologies are increasingly being applied to minute
tumor samples such as those obtained from biopsies.
Moreover, the recent development of the one million
(1 M) probe array CGH platform by Agilent offers an
ultra-high (2.1 kb) resolution definition of DNA copy
number alterations. The potential advantage of such
ultra-high resolution is the better delineation of DNA
breakpoints at DNA copy number alterations as well as
the identification of very small, focal CNAs and CNVs.
However, several challenges are posed by the use of
such technologies in ever smaller clinical samples. First,
how small are the micro-CNAs that can be reliably
detected by ultra-high resolution microarrays? Second,
can they reliably detect small CNAs using the minute
quantities of DNA (e.g. 10-50 ng) extracted from small
biopsy samples? In order to obtain enough DNA from
such samples, one usually performs whole genome
amplification (WGA) of DNA extracted from these sam-
ples [11,12]. Does the amplification process introduce
artifacts that can confound the analysis of data gener-
ated by such high sensitivity technologies [13,14]? As
array CGH is increasingly being performed in clinical
“biomarker” studies, it is necessary to have a clear
understanding of the limitations of this technology in
these contexts. To this end, we performed a study to
answer two questions: how much sensitivity is gained by
using Agilent’s 1 M probe array CGH over the less sen-
sitive 244 K arrays, and, can one safely use whole gen-
ome amplification of DNA for these array CGH
platforms?
Using DNA from the MCF-7 breast cancer cell line,
we found that the 4-fold extra resolution of the 1 M
array platform led to the improved detection of CNVs
and intra-genic CNAs in the MCF-7 cell line, which
were mostly less than 100 Kb in genomic length. Inter-
estingly, DNA breakpoints that signal the presence of
genomic rearrangements could be detected and better
delineated using the ultra high-resolution platform.
However, combining the 1 M Agilent array CGH plat-
form with whole genome amplification of DNA results
in the appearance of many artifacts, which, although fre-
quently distinguishable from true CNAs by the naked
eye, lead to the calling of many spurious CNAs when a
commonly used CNA detection algorithm is used. Thus
ultra-high resolution methods of detecting CNAs must
be used with great caution when WGA is required for
the analysis of samples with limiting quantities of DNA.
Results and discussion
The detection of micro-copy number alterations using
ultra-high resolution array CGH
To assess the sensitivity of ultra-dense array CGH for
the detection of small copy number alterations (CNAs)
in the genome we analyzed DNA from MCF-7 cells
with 244 K and 1 M array CGH from Agilent. The array
CGH data obtained with both platforms were remark-
ably reproducible at the genomic and chromosomal
levels. All large chromosomal aberrations were reliably
identified with both platforms (Figure 1A and 1B). We
then focused on very small CNAs or “micro-CNAs”,
defined as those measuring less than 1 Mb in genomic
length. To screen for these “micro-CNAs”,w eu s e dt h e
ADM-2 algorithm developed by Agilent and included in
the Agilent Genomic Workbench for CGH analysis.
Table 1 lists all 39 such CNAs classified by size, which
were found in the MCF-7 genome with the ADM-2
algorithm in both array platforms and includes 24 copy
number gains (amplifications) (62%) and 15 copy num-
ber losses (deletions) (38%). Three such micro-CNAs
found on chromosome 3 are shown in Figure 1B. Two
o ft h e s ec o n t a i nas i n g l eg e n e ,w h i l et h et h i r do n e ,
which is the smallest CNA detected by the 1 M array
CGH, measuring only 8 Kb in genomic length, contains
no gene (Figure 1C). In comparison, the smallest CNA
found with the 244 K platform measured 64 Kb in geno-
mic length (CNA #8 in Table 1). Thus, the performance
of both platforms reflected to some extent the relative
spacing of probes on the arrays (i.e. the 4-fold greater
resolution of the 1 M arrays).
Of these 39 micro-CNAs, 15 (38%) were found only
using the 1 M platform, and 11 of these were smaller
than 100 Kb. Indeed, only 2 of the 13 micro-CNAs
smaller than 100 Kb were detected by the 244 K array,
while all but 3 of the 26 micro-CNAs greater than 100
Kb in length were detected by both arrays, suggesting
that the threshold of sensitivity for the detection of
s m a l lC N A sf o rt h e2 4 4Ka r r a yp l a t f o r mi sa b o u t
100 Kb in chromosomal length. Four CNAs larger than
100 Kb were not detected by the 244 K arrays in our
experiments. Two of these were low-level copy number
changes, and thus not as likely to be called by the
ADM-2 tool, and the other two were better delineated
at the higher resolution provided by the 1 M arrays. Of
the 15 micro-CNAs detected only by the 1 M array
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Figure 1 Copy number alterations (CNAs) found in a genome of MCF-7 cells with ultra-dense array CGH platforms. Genomic DNA from
MCF-7 cells was hybridized to slides containing either 244 K oligonucleotide probes (green) or 1 M oligonucleotide probes (red). (A) The whole
genome view of overlaid moving averages (2 Mb window) for log2 ratios of fluorescence between labeled MCF-7 DNA and the differentially
labeled normal human reference. (B) Zoom-in on chromosome 3 showing overlaid moving averages and aberrations found with the ADM-2
algorithm. Aberrations smaller than 1 Mb in genomic length are indicated; those found with both 244 K and 1 M platforms (*) and those found
with the 1 M platform only (#). (C) Zoom-in on the smallest aberration, 8 Kb amplification, found only with the 1 M platform. Overlaid data
points for log2 ratios obtained with 1 M platform and 244 K platform are shown (green: values below log2 = -0.5; red: values above log2 = 0.5;
black: values above log2 = -0.5 and below log2 = 0.5). Aberrations called by the ADM-2 algorithm are identified by a shaded area, and the
presence of CNVs is indicated with red boxes (bottom).
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Page 3 of 13Table 1 All CNAs smaller than 1 Mb, identified with both ultra-dense platforms
# Chromosome Start position of CNA
found only with 1 M
platform
Start position of CNA
found with both
platforms
Amplification
(A) or Deletion
(D)
Length
of CNA
Presence
of known
CNV
Number of
genes
involved
Names of
genes
involved
1 3 194,358,885 A 8,065 CNV 0
2 1 150,841,957 D 9,482 CNV 0
3 7 109,230,336 D 9,874 CNV 0
4 7 141,698,634 D 15,534 CNV 0
5 17 4,986,617 A 20,455 1 USP6
6 17 59,743,208 A 31,300 1 PECAM1
7 1 72,539,143 A 40,168 CNV 0
8 18 3.210,260 A 64,250 3 MYOM1
MYL12A
MYL12B
9 6 79,024,557 D 67,293 CNV 0
10 12 38,617,085 D 68,417 1* SLC2A13
11 12 9,528,590 D 81,464 CNV 0
12 12 38,437,305 A 91,984 1* SLC2A13
13 15 32,482,458 D 96,025 CNV 1 GOLGA8A
14 5 59,959,592 A 133,110 2 DEPDC1B
ELOVL7
15 17 78,519,743 A 133,802 2 B3GNTL1
METRNL
16 20 48,722,374 A 133,933 CNV 2 BCAS4
PARD6B
17 8 39,356,595 A 148,661 CNV 2 ADAM5P
ADAM3A
18 14 37,104,288 A 149,393 1 FOXA1
19 20 3,656,779 A 159,562 7 C20orf27
MAVS
C20orf29
CDC25B
CENPB
SPEF1
HSPA12B
20 20 55,111,937 A 175,024 1 BMP7
21 4 91,703,176 D 178,258 1 FAM190A
22 6 151,895,709 A 190,191 2 C6orf97
ESR1
23 1 112,169,367 A 202,264 1 KCND3
24 9 21, 842,925 D 221,323 CNV 4 MTAP
CDKN2A
CDKN2B
CDKN2BAS
25 20 14,879,882 D 229,686 1 MACROD2
26 1 200,010,125 D 242,671 7 NAV1
IPO9
SHISA4
LMOD1
TIMM17A
RNPEP
ELF3
27 1 120,065,684 A 349,836 CNV 6 PHGDH
HMGCS2
REG4
NBPF7
ADAM30
NOTCH2
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Page 4 of 13platform, 9 micro-CNAs were localized to sites of com-
mon copy number variations (CNVs) as per the Toronto
CNV database integrated in the Agilent Genomic Work-
bench and 7 of these contained no genes (Table 1).
Three of these measured less than 10 Kb in genomic
length. Since the normal counterpart for MCF-7 cells is
not available, it is not possible to determine if these
CNVs are truly somatic in this case.
Fourteen of the 39 (36%) micro-CNAs involved only a
single gene (Figure 2A), including 7 DNA copy gains
and 7 DNA copy losses. Five of the 15 micro-CNAs
detected only by the 1 M arrays involved one gene each
and 3 larger regions involved 3-4 genes each. The five
single gene micro-CNAs detected only by 1 M arrays
w e r e3D N Ac o p yg a i n sa n d2D N Ac o p yl o s s e s .O n e
gene (SLC2A13) was affected twice, i.e. by a DNA copy
gain and a DNA copy loss involving different segments
of the gene (Figure 2B), and the 3 other affected genes
were: USP6 (gain) (Figure 2C), PECAM1 (gain),
FAM190A (loss).
Interestingly, a DNA copy number loss of a small frag-
ment of chromosome 9 next to the CDKN2A (p16) gene
observed in the 244 K arrays was better mapped in the
1 M arrays, and was found to include the CDKN2A
(p16) gene as well as the neighboring MTAP gene
(Figure 2D). The MTAP gene has been reported to be a
Table 1 All CNAs smaller than 1 Mb, identified with both ultra-dense platforms (Continued)
28 17 56,240,772 A 384,084 1 BCAS3
29 7 64,328,811 D 393,567 CNV 3 ZNF92
INTS4L1
INTS4L2
30 4 182,164,553 D 410,882 0
31 7 157,963,956 A 413,345 4 PTPRN2
NCAPG2
FAM62B
WDR60
32 1 147,203,277 D 441,554 CNV 3 LOC645166
LOC388692
FCGR1C
33 17 70,788,571 A 541,784 CNV 14 SLC25A19
GRB2
KIAA0195
CASKIN2
TSEN54
LLGL2
RECQL5
SAP30BP
ITGB4
GALK1
H3F3B
UNK
MYO15B
LOC643008
34 9 637,589 A 558,789 4 KANK1
DMRT1
DMRT3
DMRT2
35 17 42,299,184 A 602,830 8 WNT9B
GOSR2
RPRML
CDC27
MYL4
ITGB3
C17orf57
LOC100272146
36 3 176,160,173 A 678,671 1 NAALADL2
37 3 117,722,695 D 680,165 1 LOC285194
38 1 107,928,934 A 910,775 4 VAV3
SLC25A24
NBPF4
NBPF6
39 12 32, 954,990 A 988,660 1 SYT10
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Figure 2 Micro-CNAs smaller than 1 Mb in genomic length. (A) Distribution of number of genes within micro-CNAs discovered with both
244 k and 1 M arrays. (B, C and D) Examples of micro-CNAs found only with 1 M platform. Panels show DNA copy number data points and
moving averages for the 1 M platform (top, shown in red) or 244 K platform (middle, shown in green). Aberrations are identified by shaded
blocks, genes by shaded blue boxes, and the presence of CNVs is indicated with red boxes (bottom). (B) Amplification and deletion within
SLC2A13 gene. (C) Amplification of USP6 gene. (D) Deletion of MTAP gene.
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Page 6 of 13candidate tumor suppressor gene [15,16]. To our knowl-
edge we are the first to report copy number losses of
MTAP and CDKN2A in this cell line and to associate a
CNV to this DNA site.
In all, 84 named genes were involved in micro-CNAs
(Table 1). We performed a gene ontology search for
common biologic processes affected by these genes
using the publicly accessible DAVID bioinformatics
resources http://david.abcc.ncifcrf.gov, version 6.7. The
biologic process category of “cell cycle” was the only
gene ontology term enriched with a p value < 0.01 in
this gene set (p = 0.0055). This category included 9
genes: NOTCH2, PARD6B, CDKN2A, CDKN2B,
NCAPG2, PHGDH, CDC27, CDC25B, LLGL2.O fn o t e ,
five genes involved in micro-CNAs were associated with
estrogen receptor (ER) signaling: FOXA1, BMP7, ESR1
VAV3 and PARD6B [17-20]. Interestingly, FOXA1 is a
candidate biomarker of poor prognosis in breast tumors
[17], BMP7 is a biomarker of bone metastasis in breast
cancer [21] and VAV3 is an oncogene, which maps to a
910Kb amplified region and is known to be overex-
pressed in MCF-7 cells [19]. Taken together, our find-
i n g ss u g g e s tt h a tu l t r a - h i g hr e s o l u t i o na r r a yC G H ,
especially the 1 M Agilent platform, leads to the detec-
tion of micro-CNAs involving both CNVs and genes
with a high degree of sensitivity.
The detection of breakpoints of chromosomal
rearrangements by array CGH
The formation of chromosomal rearrangements such as
translocations as well as genomic deletions and amplifi-
cations involves double strand DNA breaks [22]. In our
data, several genes involved in micro-CNAs (9 genes or
10% of all involved genes) mapped to CNAs in close
proximity of known break points or hot spots in chro-
mosomes. Those CNAs were either DNA copy number
gains (USP6, NAALADL2, BCAS4, DEPDC1B/ELOVL7,
BCAS3) (Figure 2C, 3A and 3B) or losses (FAM190A,
MACROD2, MTAP)( F i g u r e2 D )[ 2 3 - 3 1 ] .M o r e o v e r ,
using the 1 M array CGH platform, we observed several
sites of apparent intra-genic alterations in DNA copy
number, suggestive of DNA breakage within genes. We
hypothesize that such intra-genic DNA breaks may in
some cases indicate gene fusion events. Indeed, recent
evidence suggests that such fusion events are more com-
mon than previously thought [32]. Hampton et al.
recently published a list of gene fusions that involve
splicing sites of intact coding exons discovered in the
MCF-7 cell line using a parallel sequencing approach
[28]. Sixteen distinct genes are involved in these gene
fusions in MCF-7 cells, in 4 intra-chromosomal events
(1 translocation and 3 inversions) and 6 inter-chromoso-
mal rearrangements, mapping to 6 different chromoso-
mal areas in total (Table 2). Fourteen of these sixteen
genes are contained in chromosomal segments affected
by DNA copy number gains in the MCF-7 cell line. In
our array CGH data, we found that 10 of these 16 genes
(Table 2) contained intra-genic copy number alterations,
mostly complex changes in DNA copy number. Four of
these genes (DEPDC1B, ELOVL7, BCAS3 and BCAS4)
involved regions of micro-copy number alterations that
we identified and listed in Table 1 (Figure 3A and 3B),
while the others involved larger chromosomal rearrange-
ments. The one intra-chromosomal translocation invol-
ving the DEPDC1B and ELOVL7 genes was detected as
an increase in DNA copy number involving both adja-
cent genes, but breaking each of them within the gene
(Figure 3A). Interestingly, three of the 16 genes (ARF-
GEF2, SULF2 and PRKCBP1) were contained in one
large segment of chromosome 20 affected by DNA copy
number gain and two others (PTPRG and ATXN7)i na
large segment of chromosome 3 adjacent to the FRA3B
fragile site (Figure 3C). Thanks to the ultra-dense spa-
cing of probes on the arrays we were able to break
down such large chromosomal segments into smaller
regions which differ in copy number values and most
likely reflect complex sequence rearrangements (Figure
3B and 3C). These findings suggest that array CGH can
also detect chromosomal breaks and rearrangements,
which are often accompanied by DNA copy number
gains or amplifications. Moreover, ultra-dense array
CGH may become a tool to identify gene fusion events
similar to what was already suggested for high-resolu-
tion single nucleotide polymorphism genomic microar-
ray (SNP-Chip) [33].
Ultra-dense array CGH analysis reveals micro-
amplifications and micro-deletions, which are artifacts
inherent to the whole genome amplification
To determine the effect of whole genome amplification
(WGA) on the detection of micro-CNAs using the
ultra-high density platforms, we compared array CGH
results from amplified DNA to non-amplified DNA
from the MCF-7 cell line, using both the 1 M and 244
K arrays. The array CGH data obtained with 244 K and
1 M arrays (Figure 4C and 4D) was remarkably reprodu-
cible at the genome and chromosomal levels regardless
if DNA was amplified or not. However, further magnifi-
cation to the sub-chromosomal level revealed many
repetitive, periodic artifacts in amplified samples (Figure
4A and 4B). This “wave” effect was manifested as the
more or less regular periodic appearance of discrete
decreases in DNA copy number values spanning about
10-100 Kb, and occurring approximately every 50-500
Kb along each chromosome, with an amplitude of
approximately 1-1.5 log2 ratio values. These log2 ratio
value dips were observed in all genomic regions includ-
ing those of altered copy number (Figure 4A and 4B).
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Figure 3 Three intra-genic “breaks” detected with ultra-dense array CGH analysis, mapping to known gene fusions in the MCF-7
genome. Each panel shows data points and moving averages for log2 ratios of fluorescence between labeled MCF-7 DNA and the differentially
labeled normal human reference obtained with 1 M platform (top, shown in red) or 244 K platform (middle, shown in green). Aberrations are
identified and the presence of common CNVs is indicated with red boxes (bottom). (A) Amplification affecting DEPDC1B and ELOVL7 genes. Note
that the amplification starts within the DEPDC1B gene and ends within the ELOVL7 gene, corresponding to an intrachromosomal translocation
involving the N-terminus of DEPDC1B gene and the C-terminus of the ELOVL7 gene [28]. (B) A view of large amplified segment centered around
a “relative” DNA copy number loss within the BCAS3 (Breast Carcinoma Amplified Sequence 3) gene, corresponding to a gene fusion event
involving exons 6-24 or the middle part of the BCAS3 gene [28]. (C) Two genes, PTPRG and ATXN7 (indicated by solid arrows) involved in two
different gene fusion events in MCF-7 cells [28] and flanking large amplified segments of chromosome 3 (shaded area) adjacent to the FRA3B
fragile site, which contains the FHIT gene (broken arrow).
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Page 8 of 13This phenomenon considerably confounded the calling
of aberrations by the ADM-2 algorithm. We repeated
WGA in 3 separate experiments and found that the
number of aberrations called by the ADM-2 algorithm
in the entire genome varied from 125 in experiment #1
to 561 in experiment #2 and 778 in experiment #3.
S i n c eo n l y3 9o ft h o s ea b e r r a t i o n sw e r ef o u n dw h e n
non-amplified DNA was used for analysis, most of these
apparent CNAs are in fact artifacts of DNA amplifica-
tion. Thus, the number of artifacts greatly exceeded the
number of true aberrations. In experiment #1, with the
smallest number of artifacts, the majority of them
appeared as DNA copy number losses (68.8%). We also
found that only 21% of “false” aberrations were found in
all three experiments, suggesting that most DNA copy
number artifacts are produced randomly during the
WGA process. These “wave” artifacts are easily detect-
able visually in amplified samples analyzed with 1 M
platform. Thus, they are not associated specifically with
the ADM-2 algorithm. In contrast with the 1 M plat-
form, the use of the 244 K array CGH platform after
WGA did not result in such a dramatic number of arti-
facts. Indeed, the “wave” effect was hardly visible with
this platform (Figure 4E and 4F). In three independent
experiments performed with amplified DNA the num-
ber of aberrations varied from 38 in experiment #1 to
36 in experiment #2 and 35 in experiment #3, com-
pared to a total of 24 micro-CNAs when non-amplified
DNA was used for analysis. Thus, the number of poten-
tial artifacts was small relative to that found with the
denser 1 M platform. In addition, 71% of those
artefactual CNAs were common to all three replicates,
suggesting that the artifacts observed in this platform
may be more dependent on sequence context. Thus, the
ultra-dense array CGH platforms, especially the densest
1 M arrays, detect artifacts inherent to WGA and
should be used only with non-amplified DNA samples
to detect micro-CNAs.
Conclusion
Our goal is to identify novel targets for therapy and
molecular biomarkers with greater precision starting
from an in-depth analysis of CNAs present in the breast
cancer genome. The advent of ultra-high resolution
genomic analysis allows the discovery of novel and very
small CNAs hitherto undetectable before, which may
i n v o l v eo n l ys i n g l eg e n e s .I nt h i sf i r s tr e p o r to ft h eu s e
of the ultra-dense 1 M array CGH Agilent platform for
the analysis of DNA from cancer cells, we detected pre-
viously unknown intra-genic CNAs affecting genes in
the MCF-7 breast cancer cell line, some of which are
potentially relevant to cancer biology. Indeed we found
that the limit of sensitivity of detection of CNAs of the
244 K array CGH platform is approximately 100 Kb.
We have shown that a significant number of smaller
micro-CNAs (15 out of total 39, 38%) were only
detected by the 1 M array; this includes 9 CNVs as well
as two novel amplicons involving the USP6 and the
PECAM1 genes. Micro-CNAs that cut through exonic
sequences may indicate potential sites of chromosomal
rearrangements and translocations. We found that sev-
eral gene fusions present in the MCF-7 cell line were
Table 2 Genes involved in chromosomal rearrangements in MCF-7 cells, as identified by Hampton et al
Genes Type of rearrangement Intra-genic break (detected by array
CGH)
Copy number alteration (detected by array
CGH)
ARFGEF2 intrachromosomal inversion yes Amplification
ASTN2 interchromosomal no
ATXN7 interchromosomal yes Amplification
BCAS4 interchromosomal and intrachromosomal
inversion
yes Amplification
BCAS3 interchromosomal yes Amplification
DEPDC1B intrachromosomal translocation yes Amplification
ELOVL7 intrachromosomal translocation yes Amplification
NPEPPS intrachromosomal inversion no Amplification
PRICKLE2 interchromosomal no Amplification
PRKCBP1 intrachromosomal inversion no Amplification
PTPRG interchromosomal yes Amplification
RAD51C interchromosomal no Amplification
RSBN1 interchromosomal yes Amplification
SULF2 interchromosomal yes Amplification
TBC1D16 interchromosomal no
USP32 intrachromosomal inversion yes Amplification
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Figure 4 Array CGH using 1 M platform and whole genome amplified DNA reveals artifacts due to whole genome amplification. Array
CGH of whole-genome amplified DNA from the MCF-7 cell line compared to non-amplified DNA, with magnification of two small segments in
chromosomes 1 and 2. (A, B) Data obtained with 1 M platform. In three independent experiments (top 3 sections) DNA was amplified using the
Phi29 polymerase kit. The fourth experiment (bottom section) was performed without WGA. Arrows indicate some of the WGA artifacts. (C, D)
Array CGH results from the 1 M platform shown as overlaid moving averages obtained in 4 experiments; 3 with WGA-DNA (blue, green, red) and
1 without amplification (purple). (C) Zoom-out on chromosome 1. (D) Zoom-out on chromosome 2. (E, F) Data obtained with 244 K platform. In
three independent experiments (top 3 sections) DNA was amplified using Phi29 polymerase kit. The fourth experiment (bottom section) was
performed without WGA. Note the small “wave” effects are seen only in the 1 M arrays when using WGA.
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Page 10 of 13also marked by complex intra-genic DNA copy number
changes detected by ultra-dense array CGH.
In order to apply these technologies to the kind of
small biopsy samples increasingly being collected in
modern clinical trials, whole genome amplification is
frequently required to obtain sufficient quantities of
DNA. Using a commercially available and widely used
DNA amplification kit, we found that the higher sensi-
tivity of the 1 M microarray results in the cluttering of
the array CGH profile by hundreds of “wave” artifacts.
Importantly, these “wave” artifacts do not obscure the
detection of true CNAs, even when these are intra-
genic and less than 1 Mb in length. On the other hand,
the appearance of many artefactual CNAs limits the
analysis of the data at the sub-chromosomal level and
the use of copy number detection algorithms such as
ADM-2. In this study we did not perform a comparison
between DNA from fresh or frozen cells versus that
extracted from paraffin-embedded samples. In our
experience, the genetic material extracted from such
samples is of poorer quality and very small focal DNA
copy number changes are more difficult to detect. How-
ever there is no reason to suppose that the WGA-
related artifacts would not be apparent in poorer quality
DNA.
Overall, we have demonstrated the remarkable capacity
of ultra-dense array CGH platforms for discovery of can-
cer genes and biomarkers, but we have also shown that
such powerful technology requires excellent quality of
genomic DNA and does not tolerate relatively small
imperfections related to the whole genome amplification.
Methods
Cell line
The MCF-7 cell line was cultured in RPMI 1640 (R8758;
Sigma, St Louis, MO) supplemented with 10% fetal
bovine serum (Hyclone, Logan, UT). Cells in the expo-
nential phase of growth were harvested and DNA
extracted using the QuiAmp DNA extraction kit.
Array CGH
Copy number alterations (CNA) within the MCF-7 gen-
ome relative to the sex-matched normal human DNA
(Promega, Madison, WI) were identified by array CGH
analysis using microarray slides, which contain 244 000
(244 K) and one million (1 × 1 M) oligonucleotide
probes (Agilent Technologies, Santa Clara, CA, USA).
For sample preparation and hybridization we have fol-
lowed the protocol developed and described in detail by
Agilent. Briefly, genomic DNA was extracted from
MCF-7 cells using QIAmp DNA Mini Kit (Qiagen, Mis-
sissauga, Ontario, Canada). The integrity of DNA was
confirmed with nanodrop and agarose gel electrophor-
esis. For array CGH without WGA, we used 2.5 μgo f
MCF-7 DNA and 2.5 μg of reference DNA for each ana-
lysis. DNA was digested with Rsa I and Alu I and
labeled by random priming using either Cy5-dUTP or
Cy3-dUTP. Following purification with Microcon Cen-
trifugation Filters, Ultracel YM-30 (Millipore, Billerica,
Ma, USA), probes were denatured and pre-annealed
with 50 μg of human Cot-1 DNA (Invitrogen, Burling-
ton, Ontario, Canada). Hybridization was performed at
65 °C for 40 h with constant rotation.
After hybridization, slides were washed according to
the manufacturer’s instructions and scanned immediately
with a DNA Microarray Scanner (Agilent Technologies).
Data were extracted from scanned images using Feature
Extraction software, version 10.7.3.1 (Agilent). The text
files were then imported for analysis into Genomic
Workbench, standard edition 5.0.14 (Agilent). We used
the Aberration Detection Method 2 (ADM-2) algorithm
to identify DNA copy number aberrations. The ADM-2
algorithm identifies all aberrant intervals in a given sam-
ple with consistently high or low log ratios based on the
statistical score. It then samples adjacent probes to arrive
at an estimation of the true range of the aberrant seg-
ment. The statistical score represents the deviation of the
average of the log ratios from the expected value of zero,
in units of standard deviation. The algorithm searches for
intervals in which a statistical score based on the average
quality weighted log ratio of the sample and reference
channels exceeds a user specified threshold. Although a
threshold of 6 is recommended in the instruction man-
ual, we used a conservative threshold of 10 because visual
inspection of the array plots led to the rejection of several
aberrations called using the lower threshold. We applied
a filtering option of minimum of 5 probes in region and
minimum absolute average log2 ratio > 0.3. USCS human
genome assembly hg18 was used as a reference and copy
number variations (CNV) were identified with a database
integrated in the Agilent Genomic Workbench analytic
software.
Whole genome amplification
For array CGH with WGA, we used 60 ng of both
MCF-7 and reference DNA for each analysis. In this
case, whole genomic DNA was amplified using Genomi-
Phi V2 DNA Amplification Kit (GE Healthcare UK Lim-
ited, Buckinghamshire, UK), which uses random primers
to target the entire DNA template and  29 DNA poly-
merase. WGA generated 7-10 μg of labeled DNA
(MCF-7 and reference DNA) for hybridization. Ampli-
fied DNA was labeled and purified exactly the same way
as digested, non-amplified DNA.
List of abbreviations
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